Consistently, subgroup analysis of patients with EGFR mutation from IMPOWER 150 study also demonstrated a superior efficacy of the addition of atezolizumab to bevacizumab and chemotherapy than the standard of care.40 Taken together, these findings suggest that the chemo-immunotherapy combination is a promising strategy in previously treated patients with EGFR-mutant advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.